5. Method according to claim 1, wherein the inhibitor is selected from acridine derivatives, quinoline derivatives, isoquinoline derivatives and combinations thereof.

Q2

6. Method according to claim 1, wherein the inhibitor is GF120918, XR 9051 or XR 9576.

7. Method according to claim 1, wherein the bioenhancer is a mycotoxin.

9. Method according to claim 1, wherein the bioenhancer has a higher affinity for BCRP than for P-gp.

Q3

10. Method according to claim 1, wherein the bioenhancer has a higher affinity for BCRP than for MRP.

11. Method according to claim 1, wherein the bioenhancer inhibits binding of ATP to a BCRP mediated and/or related drug transport protein.

13. Method according to claim 1, wherein the pharmaceutically active compound is selected from the group consisting of indolizino-quinoline derivatives, camptothecin derivatives, anthraquinone derivatives and quinazoline derivatives.

Q4

23. Use of a pharmaceutically active compound in combination with a bioenhancer as defined in claim 1 as active ingredients in the preparation of a pharmaceutical composition for oral delivery of the pharmaceutically active compound, said pharmaceutical composition providing an increased systemic exposure of cells selected from tumor cells and normal cells to said pharmaceutically active compound in comparison to a corresponding pharmaceutical composition in which said bioenhancer is absent.

Q5

24. Use of a pharmaceutically active compound in combination with a bioenhancer as defined in claim 1 as active ingredients in the preparation of a pharmaceutical composition for oral delivery of the pharmaceutically active compound, said pharmaceutical composition providing an increased reversal of drug resistance in human and animal disorders related to overexpression of BCRP.

Q6

27. Use of a compound selected according to claim 26 as bioenhancer in a pharmaceutical composition.